Can Biogen Idec’s (NASDAQ:BIIB) promising multiple sclerosis pill be derailed -- or at least delayed -- by a rival drug maker? The big Israeli drug company Teva Pharmaceutical Industries (NYSE:TEVA) petitioned the US Food and Drug Administration to hold off on approving Biogen’s experimental MS drug known as BG-12 until medical experts can convene to review the safety of the treatment. The FDA is scheduled to make an approval decision on BG-12 by the end of March. Teva which sells the MS drug Copaxone says in its “citizen petition” to the FDA that “it is especially important for the ...